Study On The Performance And Safety Of The LEDINBIO CE Device On Visual Acuity In Subjects With Cataract

Inclusion Criteria:

1. Subject diagnosed with nuclear sclerotic (NS) lens opacities cataract, LOCS IIIgrade 1 to 3 (moderate), as confirmed by the Investigator

2. Subject aged between 40 and 85 years of age (inclusive) at the time of consent

3. Best Corrected Visual Acuity (BCVA) of 0.3 LogMAR or worse due to cataract only

4. Subject whom the medical health history has been reviewed by the Investigator andmedical records do not contraindicate the participation to the study

5. Subject who is judged suitable for the study after ophthalmic examination carriedout by the Investigator

6. Be able and willing to follow instructions, including participation in all studyassessments and visits, according to the opinion of the investigator - includingbeing able to sit upright for at least 20 mins (duration of the treatment)

Exclusion Criteria:

1. Subject unable to give voluntary written informed consent, is unlikely to cooperateor is legally incompetent, including subjects who are institutionalised by court orofficial order, or in a dependency relationship with sponsor, testing centre orinvestigator

2. Subject who had been clinically diagnosed with any eye diseases which may impactupon the treatment, or the subject's ability to be assessed after treatment

3. Subjects with intraocular lens (IOL) implant in either eye

4. Planned replacement of crystalline lens with intraocular lens (IOL) implant withinthe planned study period

5. Subject with shallow anterior chamber

6. Subject who have had a fluorescence angiogram or any use of fluorescein within thelast 3 days

7. Subject presenting eye infection or eye damage in either eye

8. Any condition which could interfere with the subject's ability to comply with thestudy including participation in all study assessments and visits.

9. Subject who had undergone a treatment using photodynamic drugs within the last 30days. (Including but not limited to methylene blue, toluidine blue, Visudyne®,Foscan, Photofrin or 5-aminolevulinic acid/ALA)

10. Subject diagnosed with any other health condition which, in the opinion of theInvestigator, would pose a safety risk to the subject by participating in the study,or may interfere with or jeopardise the study evaluation, procedures or completion

11. Subject currently receiving treatment in another investigational study or hascompleted another investigational study within the last 30 days

12. Subject participated in the previous study with the LEDINBIO CE Device (EB-14-LAT)

13. Females who are pregnant or lactating

14. Females who are of childbearing potential (menses within the last 12 months) and nottaking adequate contraceptive precautions are excluded from the trial. Females ofchildbearing potential taking acceptable contraceptive precautions may be included.